110 related articles for article (PubMed ID: 24335109)
1. Antineoplastic effect of WIN 55,212-2, a cannabinoid agonist, in a murine xenograft model of gastric cancer.
Oh JH; Lee JY; Baeg MK; Han KH; Choi MG; Park JM
Chemotherapy; 2013; 59(3):200-6. PubMed ID: 24335109
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid receptor agonist as an alternative drug in 5-fluorouracil-resistant gastric cancer cells.
Xian XS; Park H; Choi MG; Park JM
Anticancer Res; 2013 Jun; 33(6):2541-7. PubMed ID: 23749906
[TBL] [Abstract][Full Text] [Related]
3. Involvement of the CB
Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
[TBL] [Abstract][Full Text] [Related]
4. The non-selective cannabinoid receptor agonist WIN 55,212-2 attenuates responses of C-fiber nociceptors in a murine model of cancer pain.
Uhelski ML; Cain DM; Harding-Rose C; Simone DA
Neuroscience; 2013 Sep; 247():84-94. PubMed ID: 23673278
[TBL] [Abstract][Full Text] [Related]
5. Effect of a synthetic cannabinoid agonist on the proliferation and invasion of gastric cancer cells.
Xian XS; Park H; Cho YK; Lee IS; Kim SW; Choi MG; Chung IS; Han KH; Park JM
J Cell Biochem; 2010 May; 110(2):321-32. PubMed ID: 20336665
[TBL] [Abstract][Full Text] [Related]
6. Effects of WIN 55,212-2 mesylate (a synthetic cannabinoid) on the protective action of clonazepam, ethosuximide, phenobarbital and valproate against pentylenetetrazole-induced clonic seizures in mice.
Luszczki JJ; Andres-Mach M; Barcicka-Klosowska B; Florek-Luszczki M; Haratym-Maj A; Czuczwar SJ
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1870-6. PubMed ID: 21777642
[TBL] [Abstract][Full Text] [Related]
7. The potential protective effects of cannabinoid receptor agonist WIN55,212-2 on cognitive dysfunction is associated with the suppression of autophagy and inflammation in an experimental model of vascular dementia.
Wang DP; Yin H; Kang K; Lin Q; Su SH; Hai J
Psychiatry Res; 2018 Sep; 267():281-288. PubMed ID: 29945070
[TBL] [Abstract][Full Text] [Related]
8. Effects of WIN 55,212-2 (a synthetic cannabinoid CB1 and CB2 receptor agonist) on the anticonvulsant activity of various novel antiepileptic drugs against 6 Hz-induced psychomotor seizures in mice.
Florek-Luszczki M; Wlaz A; Zagaja M; Andres-Mach M; Kondrat-Wrobel MW; Luszczki JJ
Pharmacol Biochem Behav; 2015 Mar; 130():53-8. PubMed ID: 25592741
[TBL] [Abstract][Full Text] [Related]
9. The Cannabinoid Receptor Agonist WIN55,212-2 Ameliorates Hippocampal Neuronal Damage After Chronic Cerebral Hypoperfusion Possibly Through Inhibiting Oxidative Stress and ASK1-p38 Signaling.
Wang DP; Lv QL; Lin Q; Kang K; Jin KY; Hai J
Neurotox Res; 2020 Apr; 37(4):847-856. PubMed ID: 31808139
[TBL] [Abstract][Full Text] [Related]
10. Involvement of spinal cannabinoid receptors in the antipruritic effects of WIN 55,212-2, a cannabinoid receptor agonist.
Bilir KA; Anli G; Ozkan E; Gunduz O; Ulugol A
Clin Exp Dermatol; 2018 Jul; 43(5):553-558. PubMed ID: 29424035
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid receptor agonist WIN55,212-2 and fatty acid amide hydrolase inhibitor URB597 ameliorate neuroinflammatory responses in chronic cerebral hypoperfusion model by blocking NF-κB pathways.
Su SH; Wu YF; Lin Q; Hai J
Naunyn Schmiedebergs Arch Pharmacol; 2017 Dec; 390(12):1189-1200. PubMed ID: 28825114
[TBL] [Abstract][Full Text] [Related]
12. Antiproliferative mechanism of a cannabinoid agonist by cell cycle arrest in human gastric cancer cells.
Park JM; Xian XS; Choi MG; Park H; Cho YK; Lee IS; Kim SW; Chung IS
J Cell Biochem; 2011 Apr; 112(4):1192-205. PubMed ID: 21312237
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid WIN 55,212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid-receptor 2 dependent manner.
Roberto D; Klotz LH; Venkateswaran V
Prostate; 2019 Feb; 79(2):151-159. PubMed ID: 30242861
[TBL] [Abstract][Full Text] [Related]
14. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway.
Fakhfouri G; Ahmadiani A; Rahimian R; Grolla AA; Moradi F; Haeri A
Neuropharmacology; 2012 Sep; 63(4):653-66. PubMed ID: 22634229
[TBL] [Abstract][Full Text] [Related]
15. The cannabinoid receptor agonist WIN 55,212-2 reduces the initial cerebral damage after hypoxic-ischemic injury in fetal lambs.
Alonso-Alconada D; Alvarez FJ; Alvarez A; Mielgo VE; Goñi-de-Cerio F; Rey-Santano MC; Caballero A; Martinez-Orgado J; Hilario E
Brain Res; 2010 Nov; 1362():150-9. PubMed ID: 20858469
[TBL] [Abstract][Full Text] [Related]
16. The cannabinoid receptor agonist WIN 55,212-2 inhibits antigen-induced plasma extravasation in guinea pig airways.
Fukuda H; Abe T; Yoshihara S
Int Arch Allergy Immunol; 2010; 152(3):295-300. PubMed ID: 20150748
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain.
Ahmed MM; Rajpal S; Sweeney C; Gerovac TA; Allcock B; McChesney S; Patel AU; Tilghman JI; Miranpuri GS; Resnick DK
Spine J; 2010 Dec; 10(12):1049-54. PubMed ID: 20920894
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation.
Marchalant Y; Rosi S; Wenk GL
Neuroscience; 2007 Feb; 144(4):1516-22. PubMed ID: 17178196
[TBL] [Abstract][Full Text] [Related]
19. Involvement of PPAR receptors in the anticonvulsant effects of a cannabinoid agonist, WIN 55,212-2.
Payandemehr B; Ebrahimi A; Gholizadeh R; Rahimian R; Varastehmoradi B; Gooshe M; Aghaei HN; Mousavizadeh K; Dehpour AR
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Mar; 57():140-5. PubMed ID: 25448777
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of protective effects of non-selective cannabinoid receptor agonist WIN 55,212-2 against the nitroglycerine-induced acute and chronic animal models of migraine: A mechanistic study.
Mohammadi Vosough E; Baradaran Rahimi V; Masoud SA; Mirkarimi HR; Demneh MK; Abed A; Banafshe HR; Askari VR
Life Sci; 2019 Sep; 232():116670. PubMed ID: 31330139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
